Prospective Evaluation of Different Methods for Volumetric Analysis on [18F]FDG PET/CT in Pediatric Hodgkin Lymphoma
- PMID: 36294544
- PMCID: PMC9605658
- DOI: 10.3390/jcm11206223
Prospective Evaluation of Different Methods for Volumetric Analysis on [18F]FDG PET/CT in Pediatric Hodgkin Lymphoma
Abstract
Rationale: Therapy response evaluation by 18F-fluorodeoxyglucose PET/CT (FDG PET) has become a powerful tool for the discrimination of responders from non-responders in pediatric Hodgkin lymphoma (HL). Recently, volumetric analyses have been regarded as a valuable tool for disease prognostication and biological characterization in cancer. Given the multitude of methods available for volumetric analysis in HL, the AIEOP Hodgkin Lymphoma Study Group has designed a prospective analysis of the Italian cohort enrolled in the EuroNet-PHL-C2 trial. Methods: Primarily, the study aimed to compare the different segmentation techniques used for volumetric assessment in HL patients at baseline (PET1) and during therapy: early (PET2) and late assessment (PET3). Overall, 50 patients and 150 scans were investigated for the current analysis. A dedicated software was used to semi-automatically delineate contours of the lesions by using different threshold methods. More specifically, four methods were applied: (1) fixed 41% threshold of the maximum standardized uptake value (SUVmax) within the respective lymphoma site (V41%), (2) fixed absolute SUV threshold of 2.5 (V2.5); (3) SUVmax(lesion)/SUVmean liver >1.5 (Vliver); (4) adaptive method (AM). All parameters obtained from the different methods were analyzed with respect to response. Results: Among the different methods investigated, the strongest correlation was observed between AM and Vliver (rho > 0.9; p < 0.001 for SUVmean, MTV and TLG at all scan timing), along with V2.5 and AM or Vliver (rho 0.98, p < 0.001 for TLG at baseline; rho > 0.9; p < 0.001 for SUVmean, MTV and TLG at PET2 and PET3, respectively). To determine the best segmentation method, we applied logistic regression and correlated different results with Deauville scores at late evaluation. Logistic regression demonstrated that MTV (metabolic tumor volume) and TLG (total lesion glycolysis) computation according to V2.5 and Vliver significantly correlated to response to treatment (p = 0.01 and 0.04 for MTV and 0.03 and 0.04 for TLG, respectively). SUVmean also resulted in significant correlation as absolute value or variation. Conclusions: The best correlation for volumetric analysis was documented for AM and Vliver, followed by V2.5. The volumetric analyses obtained from V2.5 and Vliver significantly correlated to response to therapy, proving to be preferred thresholds in our pediatric HL cohort.
Keywords: FDG PET; Hodgkin’s lymphoma; interim evaluation; method comparison; pediatric; response assessment; volumetric analysis.
Conflict of interest statement
The authors declare no conflict of interest.
Figures




Similar articles
-
Prognostic value of baseline and interim [18F]FDG PET metabolic parameters in pediatric Hodgkin's lymphoma.Eur J Nucl Med Mol Imaging. 2024 Jun;51(7):1955-1964. doi: 10.1007/s00259-024-06643-8. Epub 2024 Feb 14. Eur J Nucl Med Mol Imaging. 2024. PMID: 38351389
-
Additional value of volumetric and texture analysis on FDG PET assessment in paediatric Hodgkin lymphoma: an Italian multicentric study protocol.BMJ Open. 2021 Mar 29;11(3):e041252. doi: 10.1136/bmjopen-2020-041252. BMJ Open. 2021. PMID: 33782017 Free PMC article.
-
Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin's lymphoma.BMC Cancer. 2018 May 3;18(1):521. doi: 10.1186/s12885-018-4432-4. BMC Cancer. 2018. PMID: 29724189 Free PMC article. Clinical Trial.
-
Usefulness of Combined Metabolic-Volumetric Indices of (18)F-FDG PET/CT for the Early Prediction of Neoadjuvant Chemotherapy Outcomes in Breast Cancer.Nucl Med Mol Imaging. 2013 Mar;47(1):36-43. doi: 10.1007/s13139-012-0181-5. Epub 2012 Nov 17. Nucl Med Mol Imaging. 2013. PMID: 24895506 Free PMC article.
-
Assessment of Response to Immunotherapy in Patients with Hodgkin Lymphoma: Towards Quantifying Changes in Tumor Burden Using FDG-PET/CT.J Clin Med. 2023 May 16;12(10):3498. doi: 10.3390/jcm12103498. J Clin Med. 2023. PMID: 37240602 Free PMC article. Review.
Cited by
-
Preliminary Study of the Relationship between Osteopontin and Relapsed Hodgkin's Lymphoma.Biomedicines. 2023 Dec 21;12(1):31. doi: 10.3390/biomedicines12010031. Biomedicines. 2023. PMID: 38275392 Free PMC article.
-
Deciphering Tumor Response: The Role of Fluoro-18-d-Glucose Uptake in Evaluating Targeted Therapies with Tyrosine Kinase Inhibitors.J Clin Med. 2024 May 31;13(11):3269. doi: 10.3390/jcm13113269. J Clin Med. 2024. PMID: 38892979 Free PMC article.
-
Optimizing the prognostic capacity of baseline 18F-FDG PET/CT metabolic parameters in extranodal natural killer/T-cell lymphoma by using relative and absolute thresholds.Heliyon. 2024 Jan 23;10(3):e25184. doi: 10.1016/j.heliyon.2024.e25184. eCollection 2024 Feb 15. Heliyon. 2024. PMID: 38322946 Free PMC article.
-
Therapy results in pediatric Hodgkin lymphoma - does less mean better? Experience from a single children's oncology center.Ann Hematol. 2023 Aug;102(8):2109-2117. doi: 10.1007/s00277-023-05268-5. Epub 2023 May 17. Ann Hematol. 2023. PMID: 37195291 Free PMC article.
-
Prognostic value of baseline and interim [18F]FDG PET metabolic parameters in pediatric Hodgkin's lymphoma.Eur J Nucl Med Mol Imaging. 2024 Jun;51(7):1955-1964. doi: 10.1007/s00259-024-06643-8. Epub 2024 Feb 14. Eur J Nucl Med Mol Imaging. 2024. PMID: 38351389
References
-
- Hudson M.M., Krasin M.J., Kaste S.C. PET imaging in pediatric Hodgkin’s lymphoma. Pediatr. Radiol. 2004;34:190–198. - PubMed
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous